Elliott strikes back at Actelion with board nominees; NICE gives Merck's Simponi a thumbs up;

@FiercePharma: Herper: Cheap Lipitor could increase health costs. Story | Follow @FiercePharma

> Activist hedge fund Elliott Advisors is tapping six pharma executives and M&A experts to stand for election to the Actelion board, stepping up pressure for major changes at Europe's biggest biotech firm. Item

> The U.K.'s cost-effectiveness watchdog recommended Merck's injectable anti-inflammatory drug Simponi after the U.S.-based manufacturer provided more information about the product. Report

> FDA issued a warning letter to Novartis on its Ciba Vision facility in Cidra, Puerto Rico, for problems with product labeling and for continuing to use contract labs even after sterility issues. News

> ProStrakan, the pharmaceutical firm that has agreed to be bought by Japan's Kyowa Hakko Kirin, narrowed its full-year loss after bouncing back from manufacturing problems. Article

> One insider at Pfizer cashed in over half his direct holdings following a recent nearly three-year high. Story

> German drug distributor Celesio's Chief Executive Fritz Oesterle, who has had a strained relationship with the company's majority shareholder, is stepping down after more than 12 years. Item

Biotech News

@FierceBiotech: Five prostate cancer diagnostics to watch. Article  | Follow @FierceBiotech

@JohnCFierce: Novartis has mapped out a blockbuster future for INC424. Story | Follow @JohnCFierce

> Interview: Pfizer vaccine unit eyes adults, infectious disease. Report 

> FivePrime scores $495M cancer deal with Human Genome Sciences. News 

> Genfit gets up to $54M in Sanofi deal. Story 

> Astellas buys out Maxygen stake in JV for $76M. News

Vaccines News

> UK and Scotland look at foot-and-mouth disease vax program. Report 

> OSU finds new delivery tech for norovirus vax. Item 

> Daiichi recalls Sanofi ActHIB vax in Japan. Report 

> Animal data supports J&J's Alzheimer's vaccine. Story

Manufacturing News

> Hamburg: FDA needs funding to hit inspection goal. Item 

> Obama administration's track/trace recommendation lacks teeth. News

> Japan pharma stocks fall; pharma aid rises. Story 

> OTC cold drug prescriptions get mixed review among states. Article 

> Ranbaxy's manufacturing woes make Daiichi buy a 'failure'. Item

> Obama lobbies Congress for track/trace. Story 

And Finally... Unemployment and rising expenses caused 9 million Americans to lose health insurance during the past two years, according to researchers backed by a group advocating access to health care. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.